Kara A Michels1, Timothy S McNeel2, Britton Trabert3. 1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, United States of America. Electronic address: kara.michels@nih.gov. 2. Information Management Services, Inc., Calverton, MD, United States of America. 3. Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, United States of America.
Abstract
OBJECTIVE: To clarify associations between metabolic syndrome, its components, and ovarian cancer risk. METHODS: Using a case-control study within the U.S.-based Surveillance, Epidemiology and End Results (SEER)-Medicare linked database, we examined metabolic syndrome, its components (obesity, impaired fasting glucose, hypertension, HDL cholesterol, triglycerides), and ovarian/fallopian tube cancer risk. Cases (n = 16,850) were diagnosed with cancer between age 68-89 from 1994 through 2013. Controls (n = 281,878) were Medicare enrollees without these cancers living in registry areas. We estimated adjusted odds ratios (OR) and 95% confidence intervals (CI) with logistic regression. RESULTS: Women with metabolic syndrome had reduced ovarian cancer risk compared to women not meeting the diagnostic criteria (OR 0.86, CI 0.82-0.89). Having one or two syndrome components was associated with increased risk, but having ≥3 was not, when compared to women without any components. Impaired fasting glucose, which was highly prevalent among those with metabolic syndrome, was associated with reduced risk (OR 0.90, CI 0.87-0.93). Hypertension and high triglycerides, the most prevalent components among women without metabolic syndrome, were associated with increased risks (OR 1.08, CI 1.04-1.12; OR 1.05, CI 1.01-1.08, respectively). CONCLUSIONS: Specific metabolic syndrome components may have modest associations with ovarian cancer. These associations varied in direction and the prevalence of the components influenced the overall association between metabolic syndrome and ovarian cancer. Evaluating metabolic syndrome as a composite exposure could be misleading in ovarian cancer research, but further study of the syndrome components is warranted. Published by Elsevier Inc.
OBJECTIVE: To clarify associations between metabolic syndrome, its components, and ovarian cancer risk. METHODS: Using a case-control study within the U.S.-based Surveillance, Epidemiology and End Results (SEER)-Medicare linked database, we examined metabolic syndrome, its components (obesity, impaired fasting glucose, hypertension, HDL cholesterol, triglycerides), and ovarian/fallopian tube cancer risk. Cases (n = 16,850) were diagnosed with cancer between age 68-89 from 1994 through 2013. Controls (n = 281,878) were Medicare enrollees without these cancers living in registry areas. We estimated adjusted odds ratios (OR) and 95% confidence intervals (CI) with logistic regression. RESULTS: Women with metabolic syndrome had reduced ovarian cancer risk compared to women not meeting the diagnostic criteria (OR 0.86, CI 0.82-0.89). Having one or two syndrome components was associated with increased risk, but having ≥3 was not, when compared to women without any components. Impaired fasting glucose, which was highly prevalent among those with metabolic syndrome, was associated with reduced risk (OR 0.90, CI 0.87-0.93). Hypertension and high triglycerides, the most prevalent components among women without metabolic syndrome, were associated with increased risks (OR 1.08, CI 1.04-1.12; OR 1.05, CI 1.01-1.08, respectively). CONCLUSIONS: Specific metabolic syndrome components may have modest associations with ovarian cancer. These associations varied in direction and the prevalence of the components influenced the overall association between metabolic syndrome and ovarian cancer. Evaluating metabolic syndrome as a composite exposure could be misleading in ovarian cancer research, but further study of the syndrome components is warranted. Published by Elsevier Inc.
Entities:
Keywords:
Electronic health records; Epidemiology; Hypertension; Metabolic syndrome; Ovarian neoplasms
Authors: Kristin M Nieman; Hilary A Kenny; Carla V Penicka; Andras Ladanyi; Rebecca Buell-Gutbrod; Marion R Zillhardt; Iris L Romero; Mark S Carey; Gordon B Mills; Gökhan S Hotamisligil; S Diane Yamada; Marcus E Peter; Katja Gwin; Ernst Lengyel Journal: Nat Med Date: 2011-10-30 Impact factor: 53.440
Authors: Wegene Borena; Tanja Stocks; Håkan Jonsson; Susanne Strohmaier; Gabriele Nagel; Tone Bjørge; Jonas Manjer; Göran Hallmans; Randi Selmer; Martin Almquist; Christel Häggström; Anders Engeland; Steinar Tretli; Hans Concin; Alexander Strasak; Pär Stattin; Hanno Ulmer Journal: Cancer Causes Control Date: 2010-12-08 Impact factor: 2.506
Authors: Geoffrey C Kabat; Mimi Y Kim; Rowan T Chlebowski; Mara Z Vitolins; Sylvia Wassertheil-Smoller; Thomas E Rohan Journal: Cancer Causes Control Date: 2017-12-02 Impact factor: 2.506
Authors: Britton Trabert; Cassandra A Hathaway; Megan S Rice; Eric B Rimm; Patrick M Sluss; Kathryn L Terry; Oana A Zeleznik; Shelley S Tworoger Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-08-17 Impact factor: 4.090
Authors: Jeanine N Staples; Lauren C Peres; Fabian Camacho; Anthony J Alberg; Elisa V Bandera; Jill Barnholtz-Sloan; Melissa L Bondy; Michele L Cote; Ellen Funkhouser; Patricia G Moorman; Edward S Peters; Ann G Schwartz; Paul D Terry; Joellen M Schildkraut Journal: Gynecol Oncol Date: 2020-04-30 Impact factor: 5.482